Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia

Stephen A. Sands, Brian T. Harel, Mirko Savone, Kara Kelly, Veena Vijayanathan, Jennifer Greene Welch, Lynda Vrooman, Lewis B. Silverman, Peter D. Cole

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: Neurocognitive impairment is frequently observed among acute lymphoblastic leukemia (ALL) survivors within the domains of intelligence, attention, processing speed, working memory, learning, and memory. However, few have investigated treatment-induced changes in neurocognitive function during the first months of treatment. Additionally, dysfunction during treatment may be preceded by changes in biomarkers measured within cerebrospinal fluid (CSF). Identification of acute declines in neurocognitive function, as well as predictive genotypes or biomarkers, could guide therapeutic trials of protective interventions. Methods: This study collects CSF while prospectively assessing neurocognitive functioning (working memory, executive function, learning, processing speed, and attention) of ALL patients using the Cogstate computerized battery at six time points during and after the 2 years of leukemia treatment on a Dana-Farber Cancer Institute ALL Consortium trial. Results: Baseline data collected during the first 3 weeks of induction chemotherapy indicate reliable data as all subjects (N = 34) completed Cogstate baseline testing, while completion and performance checks indicate that 100 % of subjects completed testing and complied with test requirements. The majority (85 %) exhibited normal function compared with age peers. Preliminary analysis of CSF biomarkers (folate, homocysteine, 8-isoprostane, and myelin basic protein) similarly reveals values at baseline within expected normal ranges. Conclusions: The first month of induction therapy for ALL is a reliable baseline for detecting treatment-induced changes in neurocognitive functioning. Consequently, serial data collection might identify subgroups of ALL patients at increased risk for neurocognitive decline, warranting proactive interventions to improve their level of functioning both during treatment and into survivorship.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalSupportive Care in Cancer
DOIs
StateAccepted/In press - Oct 10 2016

Fingerprint

Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cerebrospinal Fluid
8-epi-prostaglandin F2alpha
Biomarkers
Therapeutics
Short-Term Memory
Learning
Induction Chemotherapy
Myelin Basic Protein
Executive Function
Homocysteine
Intelligence
Folic Acid
Survivors
Reference Values
Survival Rate
Genotype
Neoplasms

Keywords

  • Acute lymphoblastic leukemia
  • Biomarkers
  • Late effects
  • Methotrexate
  • Neurocognitive
  • Neurotoxicity

ASJC Scopus subject areas

  • Oncology

Cite this

Sands, S. A., Harel, B. T., Savone, M., Kelly, K., Vijayanathan, V., Welch, J. G., ... Cole, P. D. (Accepted/In press). Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia. Supportive Care in Cancer, 1-9. https://doi.org/10.1007/s00520-016-3422-9

Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia. / Sands, Stephen A.; Harel, Brian T.; Savone, Mirko; Kelly, Kara; Vijayanathan, Veena; Welch, Jennifer Greene; Vrooman, Lynda; Silverman, Lewis B.; Cole, Peter D.

In: Supportive Care in Cancer, 10.10.2016, p. 1-9.

Research output: Contribution to journalArticle

Sands, SA, Harel, BT, Savone, M, Kelly, K, Vijayanathan, V, Welch, JG, Vrooman, L, Silverman, LB & Cole, PD 2016, 'Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia', Supportive Care in Cancer, pp. 1-9. https://doi.org/10.1007/s00520-016-3422-9
Sands, Stephen A. ; Harel, Brian T. ; Savone, Mirko ; Kelly, Kara ; Vijayanathan, Veena ; Welch, Jennifer Greene ; Vrooman, Lynda ; Silverman, Lewis B. ; Cole, Peter D. / Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia. In: Supportive Care in Cancer. 2016 ; pp. 1-9.
@article{087b91d3ed1f494eb824420055594caf,
title = "Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia",
abstract = "Purpose: Neurocognitive impairment is frequently observed among acute lymphoblastic leukemia (ALL) survivors within the domains of intelligence, attention, processing speed, working memory, learning, and memory. However, few have investigated treatment-induced changes in neurocognitive function during the first months of treatment. Additionally, dysfunction during treatment may be preceded by changes in biomarkers measured within cerebrospinal fluid (CSF). Identification of acute declines in neurocognitive function, as well as predictive genotypes or biomarkers, could guide therapeutic trials of protective interventions. Methods: This study collects CSF while prospectively assessing neurocognitive functioning (working memory, executive function, learning, processing speed, and attention) of ALL patients using the Cogstate computerized battery at six time points during and after the 2 years of leukemia treatment on a Dana-Farber Cancer Institute ALL Consortium trial. Results: Baseline data collected during the first 3 weeks of induction chemotherapy indicate reliable data as all subjects (N = 34) completed Cogstate baseline testing, while completion and performance checks indicate that 100 {\%} of subjects completed testing and complied with test requirements. The majority (85 {\%}) exhibited normal function compared with age peers. Preliminary analysis of CSF biomarkers (folate, homocysteine, 8-isoprostane, and myelin basic protein) similarly reveals values at baseline within expected normal ranges. Conclusions: The first month of induction therapy for ALL is a reliable baseline for detecting treatment-induced changes in neurocognitive functioning. Consequently, serial data collection might identify subgroups of ALL patients at increased risk for neurocognitive decline, warranting proactive interventions to improve their level of functioning both during treatment and into survivorship.",
keywords = "Acute lymphoblastic leukemia, Biomarkers, Late effects, Methotrexate, Neurocognitive, Neurotoxicity",
author = "Sands, {Stephen A.} and Harel, {Brian T.} and Mirko Savone and Kara Kelly and Veena Vijayanathan and Welch, {Jennifer Greene} and Lynda Vrooman and Silverman, {Lewis B.} and Cole, {Peter D.}",
year = "2016",
month = "10",
day = "10",
doi = "10.1007/s00520-016-3422-9",
language = "English (US)",
pages = "1--9",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia

AU - Sands, Stephen A.

AU - Harel, Brian T.

AU - Savone, Mirko

AU - Kelly, Kara

AU - Vijayanathan, Veena

AU - Welch, Jennifer Greene

AU - Vrooman, Lynda

AU - Silverman, Lewis B.

AU - Cole, Peter D.

PY - 2016/10/10

Y1 - 2016/10/10

N2 - Purpose: Neurocognitive impairment is frequently observed among acute lymphoblastic leukemia (ALL) survivors within the domains of intelligence, attention, processing speed, working memory, learning, and memory. However, few have investigated treatment-induced changes in neurocognitive function during the first months of treatment. Additionally, dysfunction during treatment may be preceded by changes in biomarkers measured within cerebrospinal fluid (CSF). Identification of acute declines in neurocognitive function, as well as predictive genotypes or biomarkers, could guide therapeutic trials of protective interventions. Methods: This study collects CSF while prospectively assessing neurocognitive functioning (working memory, executive function, learning, processing speed, and attention) of ALL patients using the Cogstate computerized battery at six time points during and after the 2 years of leukemia treatment on a Dana-Farber Cancer Institute ALL Consortium trial. Results: Baseline data collected during the first 3 weeks of induction chemotherapy indicate reliable data as all subjects (N = 34) completed Cogstate baseline testing, while completion and performance checks indicate that 100 % of subjects completed testing and complied with test requirements. The majority (85 %) exhibited normal function compared with age peers. Preliminary analysis of CSF biomarkers (folate, homocysteine, 8-isoprostane, and myelin basic protein) similarly reveals values at baseline within expected normal ranges. Conclusions: The first month of induction therapy for ALL is a reliable baseline for detecting treatment-induced changes in neurocognitive functioning. Consequently, serial data collection might identify subgroups of ALL patients at increased risk for neurocognitive decline, warranting proactive interventions to improve their level of functioning both during treatment and into survivorship.

AB - Purpose: Neurocognitive impairment is frequently observed among acute lymphoblastic leukemia (ALL) survivors within the domains of intelligence, attention, processing speed, working memory, learning, and memory. However, few have investigated treatment-induced changes in neurocognitive function during the first months of treatment. Additionally, dysfunction during treatment may be preceded by changes in biomarkers measured within cerebrospinal fluid (CSF). Identification of acute declines in neurocognitive function, as well as predictive genotypes or biomarkers, could guide therapeutic trials of protective interventions. Methods: This study collects CSF while prospectively assessing neurocognitive functioning (working memory, executive function, learning, processing speed, and attention) of ALL patients using the Cogstate computerized battery at six time points during and after the 2 years of leukemia treatment on a Dana-Farber Cancer Institute ALL Consortium trial. Results: Baseline data collected during the first 3 weeks of induction chemotherapy indicate reliable data as all subjects (N = 34) completed Cogstate baseline testing, while completion and performance checks indicate that 100 % of subjects completed testing and complied with test requirements. The majority (85 %) exhibited normal function compared with age peers. Preliminary analysis of CSF biomarkers (folate, homocysteine, 8-isoprostane, and myelin basic protein) similarly reveals values at baseline within expected normal ranges. Conclusions: The first month of induction therapy for ALL is a reliable baseline for detecting treatment-induced changes in neurocognitive functioning. Consequently, serial data collection might identify subgroups of ALL patients at increased risk for neurocognitive decline, warranting proactive interventions to improve their level of functioning both during treatment and into survivorship.

KW - Acute lymphoblastic leukemia

KW - Biomarkers

KW - Late effects

KW - Methotrexate

KW - Neurocognitive

KW - Neurotoxicity

UR - http://www.scopus.com/inward/record.url?scp=84990884985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990884985&partnerID=8YFLogxK

U2 - 10.1007/s00520-016-3422-9

DO - 10.1007/s00520-016-3422-9

M3 - Article

C2 - 27726029

AN - SCOPUS:84990884985

SP - 1

EP - 9

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

ER -